
We conducted a zzso zzso phase 1 clinical trial in order to define the maximum tolerated dose zzso and zzso toxicity zzso of zzso in combination with zzso 

Patients with solid tumors and no other zzso treatment options were zzso zzso zzso was taken daily in combination with zzso 25 zzso administered zzso on days 1, 8, and 15 of a zzso zzso The dose of zzso started at 200 zzso and increased by 100 zzso level, until either a zzso or the final dose of 400 zzso was zzso 

Fifteen patients were enrolled in the zzso Median age was 58 zzso The majority had zzso lung zzso The study went to completion without reaching an zzso zzso zzso were zzso Three patients developed grade 3 zzso all occurring during the first cycle of zzso No objective responses were zzso Four patients had stable disease as a best response, 3 with zzso lung cancer and 1 with zzso 

Treatment was well tolerated and no zzso was seen at zzso 25 zzso and zzso 400 zzso Given that stable disease was durable in 4 patients, future studies with this combination may be zzso 

